Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111170028> ?p ?o ?g. }
- W2111170028 endingPage "130" @default.
- W2111170028 startingPage "123" @default.
- W2111170028 abstract "Background Prognostic impact of specific chromosomal aberrations in patients with relapsed multiple myeloma (MM) treated with the novel agents is briefly described. Patients and Methods We analyzed the prognostic value of an extended panel of chromosomal aberrations [del(13)(q14), del(17)(p13), t(4;14)(p16;q32), gain(1)(q21), and hyperdiploidy] by using the technique of interphase fluorescence in situ hybridization in a cohort of 102 patients with relapsed MM treated with thalidomide- or bortezomib-based protocols. Results The gain(1)(q21) had a negative impact on overall survival for patients with MM treated with thalidomide (15.7 vs. 41.3 months; P = .004). Moreover, we confirmed the negative impact of the cumulative effect of 2 or more cytogenetic changes that occur simultaneously on the overall survival in the thalidomide group (20.3 months vs. not yet reached; P = .039). We did not find any significant impact of the aberrations studied on overall survival in the bortezomib cohort of patients. Conclusion We conclude that bortezomib-based protocols are able to partially overcome the negative prognostic impact of the tested chromosomal abnormalities in patients with relapsed MM." @default.
- W2111170028 created "2016-06-24" @default.
- W2111170028 creator A5006612295 @default.
- W2111170028 creator A5008633165 @default.
- W2111170028 creator A5010273194 @default.
- W2111170028 creator A5013849848 @default.
- W2111170028 creator A5021172728 @default.
- W2111170028 creator A5021420657 @default.
- W2111170028 creator A5023316371 @default.
- W2111170028 creator A5026497781 @default.
- W2111170028 creator A5035821530 @default.
- W2111170028 creator A5039402772 @default.
- W2111170028 creator A5047238963 @default.
- W2111170028 creator A5048481697 @default.
- W2111170028 creator A5060503695 @default.
- W2111170028 creator A5061949623 @default.
- W2111170028 creator A5062620393 @default.
- W2111170028 creator A5071616317 @default.
- W2111170028 creator A5076551954 @default.
- W2111170028 creator A5077809504 @default.
- W2111170028 creator A5081355791 @default.
- W2111170028 creator A5090460126 @default.
- W2111170028 creator A5091155004 @default.
- W2111170028 date "2013-04-01" @default.
- W2111170028 modified "2023-09-30" @default.
- W2111170028 title "Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib" @default.
- W2111170028 cites W1494138467 @default.
- W2111170028 cites W1974511383 @default.
- W2111170028 cites W1990009253 @default.
- W2111170028 cites W1991287193 @default.
- W2111170028 cites W1993549070 @default.
- W2111170028 cites W1995832783 @default.
- W2111170028 cites W1997478952 @default.
- W2111170028 cites W2005850131 @default.
- W2111170028 cites W2008886056 @default.
- W2111170028 cites W2015880063 @default.
- W2111170028 cites W2027679963 @default.
- W2111170028 cites W2029006246 @default.
- W2111170028 cites W2042761416 @default.
- W2111170028 cites W2044436186 @default.
- W2111170028 cites W2045564415 @default.
- W2111170028 cites W2056013867 @default.
- W2111170028 cites W2060187655 @default.
- W2111170028 cites W2064114299 @default.
- W2111170028 cites W2067885146 @default.
- W2111170028 cites W2083107653 @default.
- W2111170028 cites W2086862058 @default.
- W2111170028 cites W2087843841 @default.
- W2111170028 cites W2091447224 @default.
- W2111170028 cites W2093757149 @default.
- W2111170028 cites W2096207943 @default.
- W2111170028 cites W2099334882 @default.
- W2111170028 cites W2108235071 @default.
- W2111170028 cites W2110486997 @default.
- W2111170028 cites W2110648338 @default.
- W2111170028 cites W2113424017 @default.
- W2111170028 cites W2115385885 @default.
- W2111170028 cites W2126351771 @default.
- W2111170028 cites W2132242107 @default.
- W2111170028 cites W2136735139 @default.
- W2111170028 cites W2142368474 @default.
- W2111170028 cites W2150101334 @default.
- W2111170028 cites W2155165473 @default.
- W2111170028 cites W2156829667 @default.
- W2111170028 cites W2163320846 @default.
- W2111170028 cites W2166508172 @default.
- W2111170028 cites W2316160054 @default.
- W2111170028 doi "https://doi.org/10.1016/j.clml.2012.11.012" @default.
- W2111170028 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23291040" @default.
- W2111170028 hasPublicationYear "2013" @default.
- W2111170028 type Work @default.
- W2111170028 sameAs 2111170028 @default.
- W2111170028 citedByCount "18" @default.
- W2111170028 countsByYear W21111700282014 @default.
- W2111170028 countsByYear W21111700282015 @default.
- W2111170028 countsByYear W21111700282016 @default.
- W2111170028 countsByYear W21111700282017 @default.
- W2111170028 countsByYear W21111700282018 @default.
- W2111170028 countsByYear W21111700282019 @default.
- W2111170028 countsByYear W21111700282020 @default.
- W2111170028 countsByYear W21111700282021 @default.
- W2111170028 countsByYear W21111700282023 @default.
- W2111170028 crossrefType "journal-article" @default.
- W2111170028 hasAuthorship W2111170028A5006612295 @default.
- W2111170028 hasAuthorship W2111170028A5008633165 @default.
- W2111170028 hasAuthorship W2111170028A5010273194 @default.
- W2111170028 hasAuthorship W2111170028A5013849848 @default.
- W2111170028 hasAuthorship W2111170028A5021172728 @default.
- W2111170028 hasAuthorship W2111170028A5021420657 @default.
- W2111170028 hasAuthorship W2111170028A5023316371 @default.
- W2111170028 hasAuthorship W2111170028A5026497781 @default.
- W2111170028 hasAuthorship W2111170028A5035821530 @default.
- W2111170028 hasAuthorship W2111170028A5039402772 @default.
- W2111170028 hasAuthorship W2111170028A5047238963 @default.
- W2111170028 hasAuthorship W2111170028A5048481697 @default.
- W2111170028 hasAuthorship W2111170028A5060503695 @default.
- W2111170028 hasAuthorship W2111170028A5061949623 @default.
- W2111170028 hasAuthorship W2111170028A5062620393 @default.